The world is targeting fully sustainable electricity by 2050. Energy storage systems have the biggest role to play in the 100% renewable energy scenario. This paper presents an optimal method for energy storage sizing and allocation in a power system including a share of wind farms. The power system, which is used as a test system, is a modified version of the IEEE 39 bus system. The optimization is applied using novel pharmacophore modeling (PM), which is compared to state-of-the-art techniques. The objective of the optimization is to minimize the costs of power losses, peak demand and voltage deviation. The PM optimization is applied using two methods, namely, weighting factor and normalization. The optimization and simulation are applied in the DIgSILENT power factory software application. The results show that normalization of PM optimization drives the power system to less cost in terms of total power losses by up to 29% and voltage deviation by up to 4% and better covers peak demand than state-of-the-art optimization techniques.
Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Statins, widely prescribed lipid-lowering agents, have been suggested to possess anticancer activity; however, their precise mechanisms in CRC remain poorly defined. Methods: This study employed an integrated in silico–in vitro approach to investigate the therapeutic potential of Simvastatin and Lovastatin in CRC. Network pharmacology analysis identified hub genes linking the mevalonate pathway, lipid biosynthesis, and apoptosis regulation. Molecular docking was performed to assess binding affinities, followed by molecular dynamics (MD) simulations and MM-PBSA free energy calculations for stability and binding strength evaluation. In vitro cytotoxicity was validated using HCT116 and HT-29 colorectal cancer cell lines. Results: Five hub genes (HMGCR, CYP51A1, FDFT1, SCD, and LCK) were identified as key targets. Docking studies revealed strong binding affinities, with scores of −8.4 kcal·mol −1 for Simvastatin–3LCK, −9.5 kcal·mol −1 for Lovastatin–3WEG, and −9.4 kcal·mol −1 for Lovastatin–8SBI complexes. MD simulations indicated stable binding of Simvastatin with 3LCK, characterized by minimal RMSD and SASA fluctuations, whereas Lovastatin displayed higher flexibility. MM-PBSA analysis demonstrated robust binding free energies for Lovastatin–3WEG (–64.73 kcal·mol −1 ) and Simvastatin–3LCK (–56.47 kcal·mol −1 ). In vitro assays confirmed a dose-dependent reduction in cell viability, with IC 50 values of 8.9 ± 0.17 μM (Simvastatin) and 12.6 ± 0.32 μM (Lovastatin) in HCT116, compared with 14.4 ± 0.15 μM and 18.7 ± 0.53 μM in HT-29 cells, respectively. Conclusion: This integrated study demonstrates that Simvastatin and Lovastatin exert cytotoxic effects in CRC cells by targeting metabolic and apoptotic pathways. Simvastatin showed superior activity compared with Lovastatin.
7 March 2026 in Computational Biology and Chemistry